In a larger cohort, however, patients with NRAS-mutant tumors showed comparable rates of response to immunotherapy but significantly shorter overall survival compared to patients with NRAS-WT melanoma (Kirchberger et al., 2018). This evidence concerns the gene NRAS and melanoma.